Featured Story | By Nick Paul Taylor BC Partners has sold its majority stake in Pharmathen in a deal that values the sustained release drug delivery specialist at €1.6 billion ($1.9 billion). Private equity firm Partners Group has acquired the stake and outlined plans to accelerate the expansion of Pharmathen in the U.S. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Stevanato has listed its shares on the New York Stock Exchange. The IPO fell well short of Stevanato’s initial goal but still grossed $672 million to support investments in its biologics and vaccine delivery capabilities. read more By Nick Paul Taylor Junshi Biosciences is investing RMB 200 million ($31 million) in a joint venture with mRNA delivery specialist Immorna. The joint venture will start with investment from Junshi and mRNA intellectual property from Immorna. read more By Nick Paul Taylor Micron Biomedical has begun trialing a microneedle-based measles-rubella vaccine in children. The Atlanta-based drug delivery specialist said the phase 1/2 study is the first time a microneedle vaccine has been tested in pediatric subjects. read more By Fraiser Kansteiner Pfizer and two of its subsidiaries have agreed to fork over $345 million to settle years of antitrust litigation surrounding their work on the pricey anaphylaxis injectable EpiPen. Less than a month ago, a federal court dismissed racketeering and some antitrust claims against another defendant in the case, Mylan, which is now Viatris. read more |  | eBook: Drug Design and the Patient Journey Patient-focused drug design can be a key factor in real-world therapeutic outcomes and business success. But if successful treatments should be created with patients in mind, when is the optimal time to solicit this feedback? This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Learn more. |
Resources Sponsored by: Patheon by Thermo Fisher Scientific Take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within budget. Sponsored by: Patheon by Thermo Fisher Scientific Take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within budget. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: Blue Matter Consulting E-book to get newcomers “up to speed” quickly on digital health and digital therapeutics while also addressing key issues important to those already familiar with the topic. Sponsored by: WCG Engage Independent Expert Endpoint Adjudication and Data Monitoring Committees in a strategic manner to identify methods for retrospective and prospective evaluations that may improve competitive advantage and bolster regulatory submissions. Sponsored by: PA Consulting What does the future of Cell & Gene Therapy look like? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. | 
.png)
